Technical Analysis for MTNB - Matinas Biopharma Holdings, Inc.

Grade Last Price % Change Price Change
F 0.18 3.80% 0.01
MTNB closed up 3.8 percent on Wednesday, May 8, 2024, on 32 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down

Date Alert Name Type % Chg
NR7 Range Contraction 0.00%
Narrow Range Bar Range Contraction 0.00%
Earnings Movers Other 0.00%
Gapped Up Strength 0.00%
Jack-in-the-Box Bearish Bearish Swing Setup 3.80%
Stochastic Buy Signal Bullish 3.80%
Lower Bollinger Band Walk Weakness 3.80%
Inside Day Range Contraction 3.80%
Gapped Up Strength 3.80%
Lower Bollinger Band Touch Weakness 3.80%

   Recent Intraday Alerts

Alert Time
Possible NR7 about 13 hours ago
Gap Up Partially Closed about 16 hours ago
10 DMA Resistance about 16 hours ago
Gapped Up (Partial) about 17 hours ago
Rose Above Previous Day's High about 17 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Matinas Biopharma Holdings, Inc. Description

Matinas BioPharma Holdings, Inc. is a clinical-stage biopharmaceutical company. The Company is engaged in identifying and developing therapeutics for the treatment of serious and life-threatening infections. It is engaged in developing a pipeline of product and development candidates, with an initial focus on serious fungal and bacterial infections. Its cochleate delivery technology platform is designed for the targeted delivery of pharmaceuticals directly to the site of infection or inflammation. Its MAT 2203 is an oral formulation of a spectrum anti-fungal drug called amphotericin B, which uses its cochleate delivery technology. Its MAT2501 is an orally administered, encochleated formulation of the spectrum aminoglycoside antibiotic amikacin, which may be used to treat different types of multidrug-resistant bacteria, including non-tubercular mycobacterial infections (NTM), as well as various multidrug-resistant gram negative and intracellular bacterial infections.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biopharmaceutical Pharmaceutical Drugs Inflammation Infection Antibiotics Bacterial Infections Antimicrobial Resistance Drug Resistance Aminoglycoside Multiple Drug Resistance

Is MTNB a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 0.8816
52 Week Low 0.1116
Average Volume 1,765,354
200-Day Moving Average 0.22
50-Day Moving Average 0.23
20-Day Moving Average 0.19
10-Day Moving Average 0.18
Average True Range 0.02
RSI (14) 39.39
ADX 11.85
+DI 16.84
-DI 20.82
Chandelier Exit (Long, 3 ATRs) 0.16
Chandelier Exit (Short, 3 ATRs) 0.22
Upper Bollinger Bands 0.21
Lower Bollinger Band 0.17
Percent B (%b) 0.3
BandWidth 21.36
MACD Line -0.02
MACD Signal Line -0.02
MACD Histogram 0.0013
Fundamentals Value
Market Cap 38.56 Million
Num Shares 217 Million
EPS -0.10
Price-to-Earnings (P/E) Ratio -1.78
Price-to-Sales 21.78
Price-to-Book 1.97
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.19
Resistance 3 (R3) 0.19 0.18 0.19
Resistance 2 (R2) 0.18 0.18 0.18 0.19
Resistance 1 (R1) 0.18 0.18 0.18 0.18 0.18
Pivot Point 0.18 0.18 0.18 0.18 0.18
Support 1 (S1) 0.17 0.17 0.18 0.17 0.17
Support 2 (S2) 0.17 0.17 0.17 0.17
Support 3 (S3) 0.17 0.17 0.17
Support 4 (S4) 0.17